SCHEMBL4138972

SCHEMBL4138972

CCCCCCOc1ccc(/C=C2/CC/C(=C\c3ccc(OCCCCCC)cc3)C2=O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
KDM4E B2RXH2 2/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
CYP1A2 P05177 1/20 0.51
TNF P01375 1/20 0.51
IL6 P05231 1/20 0.51
BCHE P06276 3/20 0.50
ACHE P22303 3/20 0.50
PTGS2 P35354 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NR5A1 Q13285 1/20 0.49
MIF P14174 1/20 0.48
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4138976 1.00 MAPT (0.53) MAPTNPC1RAB9AKDM4ECASP3
SCHEMBL13902581 1.00 MAPT (0.53) MAPTNPC1RAB9AKDM4ECASP3
SCHEMBL14473090 0.94 CYP1A2 (0.60) MAPTNPC1RAB9AKDM4ECASP3
SCHEMBL5585137 0.94 CYP1A2 (0.60) MAPTNPC1RAB9AKDM4ECASP3
SCHEMBL5585133 0.94 CYP1A2 (0.60) MAPTNPC1RAB9AKDM4ECASP3
SCHEMBL3438449 0.85 MAPT (0.50) MAPTNPC1RAB9AKDM4ECYP1A2
SCHEMBL3438451 0.85 MAPT (0.50) MAPTNPC1RAB9AKDM4ECYP1A2
SCHEMBL9619525 0.84 CYP1A2 (0.65) MAPTNPC1RAB9AKDM4ECASP3
SCHEMBL11847128 0.84 CYP1A2 (0.60) MAPTNPC1RAB9AKDM4ECASP3
SCHEMBL11847122 0.84 CYP1A2 (0.60) MAPTNPC1RAB9AKDM4ECASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1484051-B1 Use of at least one blue-light screening agent to preserve the amount of endogenous carotenoids in the skin, new blue- light screening agents, cosmetic compositions. OREAL (FR) 2013-08-21 EP claimed
US-20090074820-A1 AMINOARYLVINYL-S-TRIAZINE COMPOUNDS AND USES THEREOF L'OREAL (FR) 2009-03-19 US claimed
US-20050008588-A1 Aminoarylvinyl-s-triazine compounds and uses thereof L'OREAL (FR) 2005-01-13 US claimed
EP-1484051-A2 Use of at least one blue-light screening agent to preserve the amount of endogenous carotenoids in the skin, new blue- light screening agents, cosmetic compositions. L'OREAL (FR) 2004-12-08 EP claimed
EP-1484051-B1 Use of at least one blue-light screening agent to preserve the amount of endogenous carotenoids in the skin, new blue- light screening agents, cosmetic compositions. OREAL (FR) 2013-08-21 EP disclosed
US-20090074820-A1 AMINOARYLVINYL-S-TRIAZINE COMPOUNDS AND USES THEREOF L'OREAL (FR) 2009-03-19 US disclosed
US-20050008588-A1 Aminoarylvinyl-s-triazine compounds and uses thereof L'OREAL (FR) 2005-01-13 US disclosed
EP-1484051-A2 Use of at least one blue-light screening agent to preserve the amount of endogenous carotenoids in the skin, new blue- light screening agents, cosmetic compositions. L'OREAL (FR) 2004-12-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008588-A1 Aminoarylvinyl-s-triazine compounds and uses thereof TYR, AAAS, ALAD MAPT 910/4885NPC1 4006/4885RAB9A 2539/4885
US-20090074820-A1 AMINOARYLVINYL-S-TRIAZINE COMPOUNDS AND USES THEREOF TYR, AAAS, ALAD MAPT 874/4885NPC1 4141/4885RAB9A 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.